MSCs engineered to express IFNβ or thymidine kinase, which is an enzyme capable of converting the prodrug ganciclovir into ganciclovir triphosphate, are now being examined for their therapeutic effects in patients with ovarian cancer and gastrointestinal cancer (Clinicaltrials.gov UNLoM. The gene discussed is IFNB1; the disease is ovarian cancer.